Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 15;13(20):5172.
doi: 10.3390/cancers13205172.

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

Giorgio Treglia  1   2   3   4   5 , Ramin Sadeghi  6 , Francesco Giovinazzo  7 , Federica Galiandro  7 , Salvatore Annunziata  8 , Barbara Muoio  9 , Alexander Stephan Kroiss  10
Affiliations
Review

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

Giorgio Treglia et al. Cancers (Basel). .

Abstract

Background: Several meta-analyses have reported quantitative data about the diagnostic performance, the prognostic value, the impact on management and the safety of positron emission tomography (PET) including related hybrid modalities (PET/CT or PET/MRI) using different radiopharmaceuticals in patients with neuroendocrine neoplasms. We performed an umbrella review of published meta-analyses to provide an evidence-based summary.

Methods: A comprehensive literature search of meta-analyses listed in PubMed/MEDLINE and Cochrane Library databases was carried out (last search date: 30 June 2021).

Results: Thirty-four published meta-analyses were selected and summarized. About the diagnostic performance: 68Ga-SSA PET yields high diagnostic performance in patients with NETs and PGL; 18F-FDOPA PET yields good diagnostic performance in patients with intestinal NETs, PGL, NB, being the best available PET method in detecting rMTC; 68Ga-exendin-4 PET has good diagnostic accuracy in detecting insulinomas; 18F-FDG PET has good diagnostic performance in detecting aggressive neuroendocrine neoplasms. About the prognostic value: 68Ga-SSA PET has a recognized prognostic value in well-differentiated NETs, whereas 18F-FDG PET has a recognized prognostic value in aggressive neuroendocrine neoplasms. A significant clinical impact of 68Ga-SSA PET and related hybrid modalities in patients with NETs was demonstrated. There are no major toxicities or safety issues related to the use of PET radiopharmaceuticals in patients with neuroendocrine neoplasms.

Conclusions: Evidence-based data support the use of PET with different radiopharmaceuticals in patients with neuroendocrine neoplasms with specific indications for each radiopharmaceutical.

Keywords: PET; diagnostic performance; impact; meta-analysis; neuroendocrine; positron emission tomography; prognosis; umbrella review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Rindi G., Inzani F. Neuroendocrine neoplasm update: Toward universal nomenclature. Endocr. Relat. Cancer. 2020;27:R211–R218. doi: 10.1530/ERC-20-0036. - DOI - PubMed
    1. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959. doi: 10.1002/cncr.11105. - DOI - PubMed
    1. Wong R.K.S., Metser U., Veit-Haibach P. Neuroendocrine Tumors: Imaging Perspective. PET Clin. 2021;16:353–364. doi: 10.1016/j.cpet.2021.03.002. - DOI - PubMed
    1. Treglia G., Kroiss A.S., Piccardo A., Lococo F., Santhanam P., Imperiale A. Role of positron emission tomography in thyroid and neuroendocrine tumors. Minerva Endocrinol. 2018;43:341–355. doi: 10.23736/S0391-1977.17.02742-0. - DOI - PubMed
    1. Taïeb D., Jha A., Treglia G., Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr. Relat. Cancer. 2019;26:R627–R652. doi: 10.1530/ERC-19-0165. - DOI - PMC - PubMed